These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29292905)

  • 1. [Register for new drugs in cancer care provides a picture of how the drugs are used in the daily clinical practice].
    Henriksson R; Falkenius J; Norin S; Öhman D; Abrahamsson M; Lindquist M; Lööv SÅ
    Lakartidningen; 2017 Nov; 114():. PubMed ID: 29292905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.
    Franck Lissbrant I; Ventimiglia E; Robinson D; Törnblom M; Hjälm-Eriksson M; Lambe M; Folkvaljon Y; Stattin P
    Scand J Urol; 2018 Apr; 52(2):143-150. PubMed ID: 29385878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New prostate cancer drugs hold promise.
    Cancer; 2013 Jan; 119(2):247-8. PubMed ID: 23292897
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.
    Nakata W; Yamamichi G; Tsujimura G; Tsujimoto Y; Nin M; Tsujihata M
    Int J Urol; 2020 Jan; 27(1):87-89. PubMed ID: 31602723
    [No Abstract]   [Full Text] [Related]  

  • 5. [Novel drugs provide better therapy for prostate cancer].
    Kellokumpu-Lehtinen P; Tammela T
    Duodecim; 2013; 129(9):923-30. PubMed ID: 23786104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
    D'Amico AV
    J Clin Oncol; 2014 Feb; 32(4):362-4. PubMed ID: 24344221
    [No Abstract]   [Full Text] [Related]  

  • 7. A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
    Badrising SK; Louhanepessy RD; van der Noort V; Coenen JLLM; Hamberg P; Beeker A; Wagenaar N; Lam MGEH; Celik F; Loosveld OJL; Oostdijk A; Zuetenhorst H; Haanen JB; Vegt E; Zwart W; Bergman AM;
    Int J Cancer; 2020 Aug; 147(4):1143-1151. PubMed ID: 31875956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer.
    Antonarakis ES
    Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
    Attard G; Antonarakis ES
    Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
    [No Abstract]   [Full Text] [Related]  

  • 10. Current approaches to incorporation of radium-223 in clinical practice.
    Parker C; Heidenreich A; Nilsson S; Shore N
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):37-47. PubMed ID: 29298991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [2017 ASCO: Complete androgen blockade strikes back].
    Penel N
    Bull Cancer; 2017; 104(7-8):599-601. PubMed ID: 28688745
    [No Abstract]   [Full Text] [Related]  

  • 12. Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer.
    Peters ML; de Meijer C; Wyndaele D; Noordzij W; Leliveld-Kors AM; van den Bosch J; van den Berg PH; Baka A; Gaultney JG
    Appl Health Econ Health Policy; 2018 Feb; 16(1):133-143. PubMed ID: 28866822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
    Pagliuca M; Buonerba C; Fizazi K; Di Lorenzo G
    Drugs; 2019 Mar; 79(4):381-400. PubMed ID: 30742279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AR-V7 predicts prostate cancer treatment response.
    Cancer Discov; 2014 Nov; 4(11):OF1. PubMed ID: 25367950
    [No Abstract]   [Full Text] [Related]  

  • 16. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.
    Glimelius B; Bergh J; Brandt L; Brorsson B; Gunnars B; Hafström L; Haglund U; Högberg T; Janunger KG; Jönsson PE; Karlsson G; Kimby E; Lamnevik G; Nilsson S; Permert J; Ragnhammar P; Sörenson S; Nygren P
    Acta Oncol; 2001; 40(2-3):135-54. PubMed ID: 11441927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].
    Brasso K; Thomsen FB; Berg KD; Røder MA; Iversen P
    Ugeskr Laeger; 2013 Sep; 175(40):2328-32. PubMed ID: 24079321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of metastatic castration-resistant prostate cancer].
    Caffo O
    Recenti Prog Med; 2015 Jan; 106(1):35-9. PubMed ID: 25621779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study on time on treatment with abiraterone and enzalutamide.
    Fallara G; Lissbrant IF; Styrke J; Montorsi F; Garmo H; Stattin P
    PLoS One; 2020; 15(12):e0244462. PubMed ID: 33370378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.